icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
 
 
 
Clinical Pharmacology of the Unboosted HIV Integrase Strand Transfer Inhibitor (INSTI) Bictegravir (BIC)
 
 
  Reported by Jules Levin
CROI 2017 Feb 14-17 Seattle, WA
 
WEBCAST: http://www.croiwebcasts.org/console/player/33377?mediaType=slideVideo&
 
Heather Zhang, Joseph M. Custodio, Xuelian Wei, Hui Wang, Amanda Vu, John Ling, Hal Martin, Erin Quirk, Brian P. Kearney
Gilead Sciences, Inc., Foster City, CA
 
----------------------------
 
Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV....http://www.natap.org/2016/HIV/062016_02.htm
 
Discovery of Bictegravir (GS-9883), a Novel, Unboosted, Once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Improved Pharmacokinetics and In Vitro Resistance Profile....http://www.natap.org/2016/HIV/062016_05.htm
 
Bictegravir (GS-9883), a Novel HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Optimized In Vitro Resistance Profile....http://www.natap.org/2016/HIV/062016_03.htm Novel Integrase Strand Transfer Inhibitor Bictegravir 10 Day Monotherapy in HIV-1-Infected Patients....http://www.natap.org/2016/HIV/062016_01.htm
 
Antiviral Activity of Bictegravir (GS-9883), a Potent Next Generation HIV-1 Integrase Strand Transfer Inhibitor....http://www.natap.org/2016/HIV/062016_04.htm
 
Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance [2].....http://www.natap.org/2016/HIV/062316_01.htm
 
ASM/ICAAC: Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance....http://www.natap.org/2016/HIV/062316_02.htm
 
-----------------

0215171

0215172

0215173

0215174

0215175